Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON’s PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv
2023年8月7日 - 9:30PM
IMUNON, Inc. (NASDAQ: IMNN), a
clinical-stage drug-development company focused on developing
non-viral DNA-mediated immunotherapy and next-generation vaccines,
announces that a manuscript titled “Strong immunogenicity &
protection in mice with PlaCCine: A COVID-19 DNA vaccine formulated
with a functional polymer,” is available on the preprint server
bioRxiv [here]. The study used IMUNON’s proprietary formulation
against the spike proteins from two SARS-CoV-2 variants, both alone
and in combination. These results add to the growing body of
preclinical data confirming the efficacy and superior desirable
features of the IMUNON’s PlaCCine vaccine modality.
Data from the study show:
- IMUNON’s proprietary formulation of
functionalized polymer protected DNA from degradation, while the
combination with an adjuvant led to an increase in protein
expression.
- DNA formulated with PlaCCine
resulted in a DNA vaccine product that was stable for up to one
year at 4°C.
- DNA formulated in PlaCCine resulted
in the induction of spike-specific neutralizing antibodies and
cytotoxic T cells.
- In the in vivo challenge model, the
vaccine-induced immune response was capable of suppressing viral
replication.
- Multiple inserts can be cloned into
the PlaCCine backbone (a plug-and-play strategy), therefore
allowing for an immune response with broader protection.
“We are delighted our manuscript was selected
for preprint and that the findings are now available to the
scientific community,” said Dr. Corinne Le Goff, president and
chief executive officer of IMUNON. “Data from this murine study
confirm PlaCCine’s potential to address SARS-CoV-2 pathogens and
mutations both as a primary vaccine and as a booster. We expect
that the plug-and-play capability we demonstrated, along with the
ability to incorporate multiple antigens in a single plasmid, will
be valuable in formulating a seasonal vaccine. Importantly, a
vaccine that is stable at standard refrigerated temperatures for up
to a year holds great commercial promise, especially in geographies
lacking the infrastructure to support the special handling needs of
mRNA vaccines.”
“We are looking forward to commencing a human
clinical trial with PlaCCine in SARS-CoV-2 during the first quarter
of 2024,” Dr. Le Goff added.
The Company plans to submit the manuscript for
publication in a peer-reviewed journal in the coming weeks.
About IMUNON
IMUNON is a fully integrated, clinical-stage
biotechnology company focused on advancing a portfolio of
innovative treatments that harness the body’s natural mechanisms to
generate safe, effective and durable responses across a broad array
of human diseases, constituting a differentiating approach from
conventional therapies. IMUNON is developing its non-viral DNA
technology across four modalities. The first modality, TheraPlas®,
is developed for the coding of proteins and cytokines in the
treatment of solid tumors where an immunological approach is deemed
promising. The second modality, PlaCCine® is developed for the
coding of viral antigens that can elicit a strong immunological
response. This technology may represent a promising platform for
the development of vaccines in infectious diseases. The third
modality, FixPlas®, concerns the application of our DNA technology
to produce universal cancer vaccines, also called tumor associated
antigen cancer vaccines. The fourth modality, which is in the
discovery phase, IndiPlas®, will focus on the development of
personalized cancer vaccines, or neoepitope cancer vaccines.
The Company’s lead clinical program, IMNN-001,
is a DNA-based immunotherapy for the localized treatment of
advanced ovarian cancer currently in Phase 2 development. IMNN-001
works by instructing the body to produce safe and durable levels of
powerful cancer-fighting molecules, such as interleukin-12 and
interferon gamma, at the tumor site. Additionally, the Company is
conducting IND-enabling preclinical studies for the development of
a COVID-19 booster vaccine: IMNN-101. The Company has also
initiated preclinical work to develop a Trp2 tumor associated
antigen cancer vaccine in melanoma: IMNN-201. We will continue to
leverage these modalities and to advance the technological frontier
of plasmid DNA to better serve patients with difficult-to-treat
conditions. For more information on IMUNON,
visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that
forward-looking statements in this news release are made pursuant
to the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. Readers are cautioned that such
forward-looking statements involve risks and uncertainties
including, without limitation, unforeseen changes in the course of
research and development activities and in clinical trials; the
uncertainties of and difficulties in analyzing interim clinical
data; the significant expense, time and risk of failure of
conducting clinical trials; the need for IMUNON to evaluate its
future development plans; possible acquisitions or licenses of
other technologies, assets or businesses; possible actions by
customers, suppliers, competitors or regulatory authorities; and
other risks detailed from time to time in IMUNON’s periodic reports
and prospectuses filed with the Securities and Exchange Commission.
IMUNON assumes no obligation to update or supplement
forward-looking statements that become untrue because of subsequent
events, new information or otherwise.
Contacts:
IMUNON |
LHA Investor Relations |
Jeffrey W. Church |
Kim Sutton Golodetz |
Executive Vice President, CFO |
212-838-3777 |
and Corporate Secretary |
Kgolodetz@lhai.com |
609-482-2455 |
|
jchurch@imunon.com |
|
# # #
Imunon (NASDAQ:IMNN)
過去 株価チャート
から 4 2024 まで 5 2024
Imunon (NASDAQ:IMNN)
過去 株価チャート
から 5 2023 まで 5 2024